The advancements in biotechnology market is revolutionizing both the diagnostic and therapeutic sciences, where in they are changing the treatment possibilities and significantly enhancing the life expectancies of patients who were earlier having remote chances of survival. According to the grand view research report, the global biotechnology market is expected to grow at a CAGR of 12.3 percent. Keen to master this opportunity, yashraj biotechnology limited(YBL: part of yashraj group) a top biotechnology firm, has established itself as a global leader in the manufacturing & marketing of various native, recombinant & cell derived antigens, and monoclonal antibodies. “we are looking to fulfill our vision to be the best in the diagnostic field and make diagnosticsaffordable and easily available to thecommon man,”avers arvind bhanushali, chairman,YBL.

YBL’s major strength lies in its unique and vast network for sourcing biomedical fluids(urine, plasma, placenta, seminal fluid,

cancer, ascitic & pleural fluids) from a wide range of national hospitals & healthcare providers pan india. Owning to safety and maintaining quality standard, this ul registered and ISO 13485:2016 and ISO 9001:2015 certified company propels procurement of human biomedical waste, production and supply chain as well as product integrity only after rigorous examinations and follow up surveillance.

YBL’s major strength lies in its unique and vast network for sourcing biomedical fluids from a wide range of national hospitals & healthcare providers PAN India

Since its inception in 1999, the company has been implementing indigenous technologies to purify high pure and part pure antigens from various human biomedical fluids. Apart from the native proteins, YBL also formulates recombinant proteins via multiple systems such as bacteria, yeast, insect and mammalian expression and also renders need based customizations & development of mutant forms and/or tagged versions of the same proteins. “we are also actively working on OEM assignments for protein purification, fast track feasibility studies and customization of biomarkers to enhance their function and stability,”adds arvind. The highest standards of quality and unwavering commitment

towards healthcare innovation have enabled YBL to capture some of the biggest market segments for various biomarker antigens and antibodies it develops and within a short span of time YBL has setup its international branches in germany, u.s. and south korea.

New Avenues: Stem Cell & Antibody Phage Display
Innovative by nature, YBL has recently stepped into the niche area of drug development and creation of disease specific model systems for preclinical testing of drugs and pharmacological compounds on pluripotent stem cells. Simultaneously, they have also started the production of recombinant antibodies through phage display. To encourage & facilitate the creation, discovery, dissemination and application of these ambitious programs, the company deploys network of technology labs (state-of-the-art facility),and associates with top national & international institutions. Through this program, YBL aims to contribute towards new drug discovery and clinicaldevelopment programs, personalized medicine for patients, stem cell, and tissue banking.

The company’s entire R&D and product development is approved by the Department of Science and Industrial Research, Ministry of Science and Technology, Government of India. “With the company celebrating 20 years of existence this year, we continue towards our mission to achieve excellence in the field and utilize its power for the good of humanity,” concludes Arvind.